Pegylated liposomal were smaller and showed greater drug entrapment efficiency than conventional liposomes. All formulations produced an increase in pulmonary absorption and circulation time of LMWH upon first dosing. Three repeated dosings of conventional liposomes resulted in decreased half-life and bioavailability; no changes in these parameters were observed with pegylated liposomes. PEG-2000 liposomes were effective in reducing thrombus weight when administered every 48 h over 8 days.
In terms of thrombolytic effects and dosing frequency, PEG-2000 liposomes administered via the pulmonary route at a dose of 100 U/kg were as effective as 50 U/kg LMWH administered subcutaneously. This paper suggests that inhalable pegylated liposomes of LMWH could be a potential noninvasive approach for DVT and PE treatment.
Bai S, Ahsan F. Inhalable Liposomes of Low Molecular Weight Heparin for theTreatment of Venous Thromboembolism. J Pharm Sci. 2010. 99:4554–4564. Correspondence to Fakhrul Ahsan, Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, at (email@example.com) or (806) 356-4015 (Ext. 335).